• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >Patented prostate cancer biomarkers
【24h】

Patented prostate cancer biomarkers

机译：专利前列腺癌生物标志物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prostate cancer is the most frequently diagnosed cancer in men. However, current diagnostic techniques (including serum PSA level measurement) lack sufficient specificity and sensitivity to determine the aggressiveness of the disease and to identify appropriate treatment. Additional reliable biomarkers are needed that can facilitate early diagnosis of prostate cancer, determine the patient's prognosis and predict responses to a given therapeutic intervention. To achieve clinical utility, biomarkers require the potential for commercialization, and such an investment is generally only made if a financial return is promised. Patenting is one way to protect the intellectual property surrounding such biomarkers and several patented biomarkers are being developed, although few have been validated in large-scale clinical trials.
机译：前列腺癌是男性中最常被诊断出的癌症。但是，当前的诊断技术（包括血清PSA水平测量）缺乏足够的特异性和敏感性来确定疾病的侵袭性和确定适当的治疗方法。还需要其他可靠的生物标志物，以促进前列腺癌的早期诊断，确定患者的预后并预测对给定治疗干预的反应。为了达到临床应用，生物标志物需要商业化的潜力，并且这种投资通常仅在保证财务回报的情况下进行。专利是保护此类生物标志物知识产权的一种方法，尽管已在大规模临床试验中得到验证，但已开发了数项获得专利的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号